Indications for FORTEO:
Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Treatment of men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture (see full labeling).
20mcg SC once daily into thigh or abdominal wall; may treat for up to 2yrs. Use for >2yrs should only be considered if a patient remains at or has returned to having a high risk for fracture.
Increased baseline risk for osteosarcoma (eg, open epiphyses, metabolic bone disease, Paget's disease of bone, bone metastases, history of skeletal malignancies, prior skeletal radiation therapy, hereditary disorders predisposing to osteosarcoma), underlying hypercalcemia disorder (eg, primary hyperparathyroidism): avoid. Risk of cutaneous calcification including calciphylaxis in those with underlying autoimmune disease, renal failure. Discontinue if calciphylaxis or worsening of previously stable cutaneous calcification develops. Urolithiasis. Hypercalciuria. Hepatic, renal, or cardiac disease. Pregnancy. Nursing mothers: not recommended.
Hormone (human parathyroid hormone, recombinant).
Caution with digoxin (teriparatide-induced hypercalcemia increases risk of toxicity). Risk of calciphylaxis when concomitant warfarin or systemic corticosteroid.
Arthralgia, pain, nausea; transient orthostatic hypotension, hypercalcemia, hyperuricemia, inj site reactions.
Prefilled pen (2.48mL)—1